Greater cardiovascular risk reduction with once-daily fixed combination of three antihypertensive agents and statin versus free-drug combination: The ALL-IN-ONE trial

Atrial FibrillationHeart, Artery and Coronary DiseasesHeart Failure

Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension

Eur Heart J.

Rea F, Corrao G, Merlino L, Mancia G

doi: 10.1093/eurheartj/ehy420.

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials

Eur Heart J.

Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, Räber L, Mach F, Windecker S

doi: 10.1093/eurheartj/ehx566.

RECOMMENDED

Lipid-Lowering Drugs

Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control

Atherosclerosis.

Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP

doi: 10.1016/

Myocardial Infarction

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Lancet.

Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group

doi: 10.1016/

RECOMMENDED

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials

Atherosclerosis.

Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP

doi: 10.1016/j.atherosclerosis.2019.06.896.

COMMENTED

Hypertension

A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial

Lancet.

Schwalm JD, McCready T, Lopez-Jaramillo P, Yusoff K, Attaran A, Lamelas P, Camacho PA, Majid F, Bangdiwala SI, Thabane L, Islam S, McKee M, Yusuf S

doi: 10.1016/S0140-

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial

Cardiovasc Drugs Ther.

Ueda S, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Morimoto T

doi: 10.1007/

RECOMMENDED

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials

Circulation.

Marston NA, Giugliano RP, Im K, Silverman MG, O'Donoghue ML, Wiviott SD, Ference BA, Sabatine MS

doi: 10.1161/

Heart, Artery and Coronary Diseases

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial

Circulation.

Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, Branch KRH, Probstfield J, Bosch J, Shestakovska O, Szarek M, Maggioni AP, Widimský P, Avezum A, Diaz R, Lewis BS, Berkowitz SD, Fox KAA, Ryden L, Yusuf S, COMPASS Steering Committee and Investigators.

doi: 10.1161/

Related content

Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials

Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials

A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial

Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial

Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial